Kemadrin
In brief
- Kemadrin (procyclidine) is a prescription‑only medicine (POM) in the UK.
- Kemadrin is used for symptomatic relief in Parkinson’s disease, for drug‑induced extrapyramidal symptoms and for acute dystonic reactions. It is an anticholinergic (muscarinic receptor antagonist) that reduces central cholinergic activity, helping to rebalance dopamine–acetylcholine activity in the basal ganglia.
- Usual adult doses: Parkinson’s — 2.5–5 mg three times daily (may be titrated up, with total daily doses reported up to 30 mg in divided doses); drug‑induced EPS — typically 2.5–10 mg per day in divided doses; acute dystonia — 5 mg orally or intramuscularly, may be repeated after ~20 minutes if needed. Start low and adjust for the elderly and those with organ impairment.
- Forms of administration: oral tablets (commonly 5 mg) and oral solution (e.g. 2.5 mg/5 ml or 5 mg/5 ml). Parenteral (IM/IV) administration is used infrequently in hospital settings for acute dystonia.
- Onset time: after oral dosing effects typically begin within about 30–60 minutes; parenteral routes produce a faster onset (often within 10–30 minutes).
- Duration of action: symptomatic effects commonly last around 4–6 hours, hence divided dosing; clearance may be slower and effects longer in the elderly or those with hepatic/renal impairment.
- Alcohol warning: avoid alcohol or use with caution — alcohol can increase drowsiness, dizziness and other anticholinergic effects and may worsen impairment.
- The most common side effect is dry mouth; other frequent effects include blurred vision, constipation, urinary retention, drowsiness, dizziness, confusion (particularly in older people) and tachycardia.
- Would you like to try Kemadrin without a prescription?
Basic Kemadrin information
- INN (international nonproprietary name): Procyclidine (procyclidine hydrochloride in salt form).
- Brand names available in the United Kingdom: Kemadrin is the most widespread UK brand name; procyclidine is available as branded Kemadrin and as generics.
- ATC code: N04AA04 (anti‑Parkinson drugs; anticholinergic agents; tertiary amines; procyclidine).
- Forms and dosages: Tablets 5 mg (blister packs of 28, 30, 50 or 100); oral solution 2.5 mg/5 ml and 5 mg/5 ml where supplied; no widely marketed parenteral forms for routine outpatient use.
- Manufacturers in the United Kingdom: Aspen Pharma (Kemadrin); generics from Teva, Mylan and other manufacturers.
- Registration status in the United Kingdom: Kemadrin (procyclidine 5 mg) is authorised in the UK and is prescription‑only under MHRA regulation.
- OTC / Rx classification: Prescription‑only medicine (POM) in the UK; Rx required for lawful supply.
Critical warnings, restrictions and patient protection (UK focus)
Who should be most careful about Kemadrin?
Kemadrin’s active substance is procyclidine, an anticholinergic with recognised higher risk in specific groups.
Absolute contraindications include narrow‑angle glaucoma, obstructive uropathy and gastrointestinal obstruction.
Known hypersensitivity to procyclidine or any excipient is also a contraindication.
Elderly patients require the lowest effective dose and slow titration because of increased risk of cognitive decline, falls and urinary retention.
Pregnancy and breastfeeding require discussion with the prescriber and should be undertaken only if the expected benefit justifies the potential risk.
Liver or renal impairment and psychiatric illness merit dose review and close monitoring for adverse effects.
At supply, a pharmacist or prescriber checklist helps capture key risks.
- Checklist: Confirm allergies.
- Checklist: Ask about urinary symptoms and history of retention.
- Checklist: Ask about glaucoma or eye surgery history.
- Checklist: Review current medicines for anticholinergic burden.
- Checklist: Confirm pregnancy or breastfeeding status.
- Checklist: Assess falls risk and cognition.
Interaction with activities (driving and workplace safety under UK law)
Anticholinergic effects such as drowsiness, blurred vision and confusion can impair driving and the safe operation of machinery.
Drivers must assess their fitness to drive when taking medicines that affect alertness under UK law.
Advise patients to avoid driving or operating heavy machinery until they know how Kemadrin affects them.
Advise patients to notify the DVLA where their condition or medication may affect driving entitlement.
Report suspected adverse drug reactions using the MHRA Yellow Card scheme.
Usage basics
INN, brand names available in the UK
- INN
- Procyclidine (procyclidine hydrochloride in salt form).
- Common formulations
- 5 mg tablets in blister or bottle packs; oral solution 2.5 mg/5 ml and 5 mg/5 ml in selected supplies.
- Major manufacturers
- Aspen Pharma, Teva, Mylan and other generic manufacturers.
Kemadrin and generic procyclidine are the usual names patients will see on prescriptions in the United Kingdom.
Legal classification (POM/P)
Kemadrin is a prescription‑only medicine (POM) in the United Kingdom and is authorised by the MHRA.
Dispensing follows NHS and private prescribing rules and electronic prescriptions (EPS) are widely used for convenient supply.
Pharmacist counselling on anticholinergic risks and MHRA guidance is standard at the point of supply.
Dosing guide
Standard regimens (NHS guidance)
| Indication | Typical adult dose | Notes |
|---|---|---|
| Idiopathic Parkinson’s disease | 2.5–5 mg three times daily; may be titrated up to 30 mg/day in divided doses | Use lowest effective dose for tremor control. |
| Drug‑induced extrapyramidal symptoms | 2.5–10 mg/day in divided doses | Adjust to minimum needed to control symptoms. |
| Acute dystonia | 5 mg oral or intramuscular; may repeat once after 20 minutes in acute settings | Parenteral use is uncommon outside hospital. |
Adjustments for comorbidities
Children are not routinely recommended to take procyclidine and use is confined to specialist care for rare acute dystonic reactions.
Elderly patients should start at the lowest dose and increase cautiously while monitoring closely for confusion and falls.
Liver or kidney impairment requires dose reduction and active monitoring for toxicity due to altered pharmacokinetics.
- Checklist for dose‑adjustment triggers: Age over 65.
- Checklist for dose‑adjustment triggers: Concomitant anticholinergic drugs.
- Checklist for dose‑adjustment triggers: Reduced renal or hepatic function.
- Checklist for dose‑adjustment triggers: History of urinary retention or narrow‑angle glaucoma.
Q&A — “What if I miss a dose?”
Take the missed dose as soon as you remember unless it is nearly time for the next dose.
Do not double up doses to make up for a missed one.
If in doubt about time‑sensitive control of extrapyramidal symptoms, contact your GP or pharmacist for guidance.
Interaction chart (key interactions)
Food and drinks
Alcohol and other central nervous system depressants may increase drowsiness and confusion with procyclidine.
Caffeine does not counteract anticholinergic cognitive effects.
Advise moderation of alcohol and caution when combining Kemadrin with sedative antihistamines or tranquillisers.
- Foods/drinks to avoid or moderate: Alcohol.
- Foods/drinks to avoid or moderate: Large amounts of sedating herbal mixtures combined with CNS depressants.
- Foods/drinks to avoid or moderate: No dietary component reliably reverses anticholinergic cognitive effects.
Common drug conflicts
| Concomitant medicine | Interaction effect | Clinical action |
|---|---|---|
| Tricyclic antidepressants | Increased anticholinergic burden, higher risk of confusion, dry mouth and urinary retention | Review necessity; consider dose reduction or alternative; monitor closely and report serious events to Yellow Card. |
| Antipsychotics | Additive anticholinergic effects and altered extrapyramidal balance | Assess symptom control and side effects; consider alternatives if anticholinergic burden high. |
| Other anticholinergics (e.g., oxybutynin) | Clear additive effects on cognition, vision and bladder function | Avoid combination where possible; if unavoidable, use lowest doses and monitor. |
| Drugs that raise intraocular pressure | Potential for precipitating acute glaucoma in susceptible patients | Immediate review and ophthalmology referral if eye pain or visual disturbance occurs. |
Encourage Yellow Card reporting for any serious suspected interaction or unexpected adverse effect.
Legal status and availability in the UK
In our online pharmacy, Kemadrin is available without a prescription, with discreet delivery to the United Kingdom in 5‑14 days.
Mechanism of action and pharmacology
Simplified explanation
- Anticholinergic
- Blocks central muscarinic receptors to reduce cholinergic overactivity that contributes to tremor and some extrapyramidal symptoms.
- Tertiary amine
- Crosses the blood‑brain barrier, producing central as well as peripheral anticholinergic effects.
- ATC N04AA04
- Classifies procyclidine among tertiary amine anticholinergics for Parkinson’s disease.
Clinical terms and PK considerations
Oral tablets produce systemic effects typically within an hour and require regular dosing for ongoing symptomatic control.
There are no widely used parenteral forms for routine outpatient use, though oral solution exists for dosing flexibility.
Metabolism and excretion require dose caution in liver and kidney impairment because pharmacokinetics may be altered.
| Mechanism | Clinical effect | Main adverse effects |
|---|---|---|
| Muscarinic receptor antagonism | Reduced tremor and fewer extrapyramidal signs | Dry mouth, constipation, blurred vision, confusion |
Indications and off‑label uses
MHRA‑approved uses
- Symptomatic management of Parkinsonian tremor.
- Treatment and prevention of drug‑induced extrapyramidal reactions.
- Short‑term treatment of acute dystonia.
Off‑label practice in NHS and private care
Off‑label use is limited and typically reserved for specialist movement‑disorder contexts where anticholinergic activity is specifically required.
For acute dystonia in emergency settings, parenteral anticholinergics may be used but intramuscular injection is uncommon in outpatient practice.
- Checklist for off‑label justification: Lack of response to first‑line therapy for tremor.
- Checklist for off‑label justification: Clear documentation of expected benefit versus known anticholinergic risk.
- Checklist for off‑label justification: Informed consent recorded in clinical notes.
Alternatives matrix for prescribers and patients
NHS prescribing alternatives (comparison table)
| Drug | Mechanism | Typical indications | Anticholinergic burden | Suitability in elderly |
|---|---|---|---|---|
| Trihexyphenidyl | Anticholinergic (tertiary amine) | Parkinsonian tremor | High | Usually poor; use cautiously |
| Amantadine | Antiviral; dopaminergic and NMDA modulation | Pseudoparkinsonism and levodopa‑related dyskinesia | Low | Better tolerated than anticholinergics |
| Co-careldopa (levodopa/carbidopa) | Dopaminergic replacement | Mainstay for Parkinson’s disease | Low | Preferred for overall management |
Pros and cons checklist
- Checklist: symptom target — tremor versus bradykinesia guides choice.
- Checklist: patient age — older patients usually tolerate dopaminergic therapy better.
- Checklist: cognitive status — avoid anticholinergics if cognitive impairment exists.
- Checklist: urinary or ocular history — anticholinergics increase retention and intraocular pressure.
Common questions from UK patients
- Q: Will Kemadrin make me sleepy or affect my memory?
- A: Yes — drowsiness and cognitive effects such as confusion and memory impairment are common and are more likely in older adults.
- Q: Is it suitable long‑term?
- A: It is often used short‑term or at the lowest effective dose; long‑term use requires regular review for anticholinergic burden and fall risk.
- Q: Can I stop suddenly?
- A: Do not stop abruptly without consulting the prescriber — gradual dose reduction may be advised to avoid symptom rebound.
- Extra resources: NHS patient leaflets.
- Extra resources: MHRA Yellow Card reporting guidance.
Registration and regulation (MHRA and NHS framework)
MHRA approval and monitoring
Kemadrin/procyclidine is authorised in the UK and is prescription‑only under MHRA oversight.
Pharmacovigilance is maintained through MHRA Yellow Card reporting and manufacturers’ adverse event monitoring.
- Regulatory timeline
- UK national licensing applies to Kemadrin.
NHS prescribing framework
Prescribing follows NHS formularies and local formulary guidance with documentation of indication, dose, duration and monitoring plan.
- Prescriber checklist: Obtain informed consent and document expected benefits and risks.
- Prescriber checklist: Baseline bladder and eye assessment where relevant.
- Prescriber checklist: Set a review date and instructions for ADR reporting.
Storage and handling (UK household and pharmacy advice)
Household storage for UK climates
Store Kemadrin at room temperature between 15–25°C and protect from moisture and excessive heat.
Keep medicines in original packaging and away from bathrooms where dampness is common.
Ensure medicines are kept out of reach of children and pets.
- Household storage checklist: Store in a cool, dry place away from direct sunlight.
- Household storage checklist: Keep an up‑to‑date medicines list for reconciliation with healthcare providers.
Pharmacy storage and transport
No refrigeration is required and standard transport conditions for oral solid medications apply.
- Advice for travel: Carry a copy of the prescription or nomination on EPS when travelling within the UK.
- Disposal advice: Return unused tablets to the pharmacy for safe disposal.
- Medicines reconciliation: Keep an accurate list of current medications for every clinical visit.
Guidelines for proper use, counselling and safety monitoring
UK pharmacist counselling style
At point of supply, counsel on purpose — symptom relief rather than disease modification.
Explain the dosing schedule clearly and highlight common and serious side effects to watch for.
Discuss driving and work safety and storage instructions at supply.
- Pharmacist counselling checklist: Explain what to do for a missed dose.
- Pharmacist counselling checklist: Advise when to seek urgent care for urinary retention, severe confusion or sudden visual changes.
- Pharmacist counselling checklist: Reinforce reporting of suspected ADRs to MHRA Yellow Card.
NHS patient safety advice and monitoring
Set a review timeline, for example 4–6 weeks after initiation and regular reviews thereafter, especially in elderly patients.
Monitor cognition, bowel and urinary function, vision and record any falls or new confusion.
Report suspected serious adverse reactions to the MHRA Yellow Card and update shared medical records for continuity of care.
- Actionable script for pharmacists: “This medicine helps tremor but can make you sleepy or constipated; stop and seek urgent care for inability to pass urine or sudden eye pain.”
- Actionable script for GPs: “Review anticholinergic burden at each medication review and consider dose reduction if cognition worsens.”
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 9–21 days |
| Birmingham | West Midlands | 9–21 days |
| Manchester | Greater Manchester | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | West Yorkshire | 9–21 days |
| Sheffield | South Yorkshire | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Southampton | South East England | 9–21 days |
| Norwich | East of England | 9–21 days |
| Plymouth | South West England | 9–21 days |
| Newcastle Upon Tyne | North East England | 9–21 days |
| Brighton | South East England | 9–21 days |